Glutamate is the major excitatory and y-aminobutyric acid (GABA) the major inhibitory neurotransmitter in mammalian brain and human cortex. Animal models of epilepsy consistently indicate that GABA synaptic function is decreased in seizure states. Extensive studies in animals have shown that changes in GABA release and metabolism may play an important role in the origin and spread of seizure activity. Although it can be inferred that the clinical benefit reported in the treatment of epilepsy is associated with and attributable to elevation of brain GABA, evidence to show changes in brain GABA levels in man is lacking. Recent advances in nuclear magnetic resonance spectroscopy (NMRS) have permitted the first non-invasive measurements of cerebral GABA in animals and man. Studies of GABA synthesis and catabolism in human cortex will further understanding of this important inhibitory neurotransmitter in human health and disease. We propose to study changes in cerebral GABA and glutamate levels in non-epileptic volunteers and patients with epilepsy. Vigabatrin (y-vinyl-y-amino butyric acid), a GABA- transaminase inhibitor, is one of the most promising new anti-epileptic drugs under development. We propose to study changes in cerebral GABA and glutamate levels in patients with epilepsy as a function of dose and time of vigabatrin administration using NlVlRS. The study has four goals: To measure in vivo cerebral GABA and glutamate levels in non-epileptic and epileptic subjects, to measure cerebral GABA levels in epileptic subjects treated with standard dose and high dose vigabatrin, to measure cerebral GABA levels of epileptic subjects before and after initiation of vigabatrin therapy, and to compare the rate of GABA accumulation following a single dose of vigabatrin with the rate of GABA turnover before and after chronic administration of vigabatrin in a rat model using 13C-labeled glucose.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS032518-02
Application #
2270768
Study Section
Neurology A Study Section (NEUA)
Project Start
1994-04-15
Project End
1997-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Yale University
Department
Neurology
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Petroff, Ognen A C; Hyder, Fahmeed; Rothman, Douglas L et al. (2006) Brain homocarnosine and seizure control of patients taking gabapentin or topiramate. Epilepsia 47:495-8
Errante, Laura D; Petroff, Ognen A C (2003) Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 12:300-6
Petroff, Ognen A C (2002) GABA and glutamate in the human brain. Neuroscientist 8:562-73
Petroff, O A; Hyder, F; Rothman, D L et al. (2001) Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures. Neurology 56:709-15
Petroff, O A; Hyder, F; Rothman, D L et al. (2001) Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 42:543-8
Petroff, O A; Hyder, F; Rothman, D L et al. (2000) Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia 41:675-80
Petroff, O A; Mattson, R H; Rothman, D L (2000) Proton MRS: GABA and glutamate. Adv Neurol 83:261-71
Petroff, O A; Hyder, F; Collins, T et al. (1999) Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia 40:958-64
Petroff, O A; Behar, K L; Rothman, D L (1999) New NMR measurements in epilepsy. Measuring brain GABA in patients with complex partial seizures. Adv Neurol 79:939-45
Petroff, O A; Rothman, D L; Behar, K L et al. (1999) Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Seizure 8:120-7

Showing the most recent 10 out of 23 publications